"FDA Warns of Intestinal Blockage Risk in Ozempic, Wegovy, and Mounjaro"

The FDA has updated the label for the weight-loss drug Ozempic, acknowledging reports of blocked intestines as a potential side effect. This update follows similar acknowledgments for the weight-loss drug Wegovy and the diabetes medication Mounjaro. While the FDA has not directly blamed the potentially life-threatening condition on the drug, there have been reports of gastrointestinal disorders associated with the use of semaglutide medications, including Ozempic and Wegovy. The FDA is monitoring these reports and will take appropriate action if necessary. Novo Nordisk, the manufacturer of Ozempic, has stated that it stands behind the safety and efficacy of its drug when used as directed.